| 000 | 00892nam a22002537a 4500 | ||
|---|---|---|---|
| 001 | D0001C000138 | ||
| 003 | DOH | ||
| 005 | 20210204134149.0 | ||
| 008 | 210204b ||||| |||| 00| 0 eng d | ||
| 245 | 0 | 2 |
_aA comparative analysis for anti-viral drugs : _btheir efficiency against SARS-CoV-2 / _cArif Kivrak [and two others] |
| 580 | _aIn: Int Immunopharmacol 2021 Jan; 90 :107232 doi: 10.1016/j.intimp.2020.107232 | ||
| 650 | 2 |
_aAntiviral Agents _xchemistry |
|
| 650 | 2 |
_aAntiviral Agents _xtherapeutic use |
|
| 650 | 2 |
_aCOVID-19 _xdiagnosis |
|
| 650 | 2 |
_aCOVID-19 _xdrug therapy |
|
| 650 | 2 |
_aCOVID-19 _xepidemiology |
|
| 650 | 2 |
_aCOVID-19 _xprevention and control |
|
| 650 | 2 | _aTreatment Outcome | |
| 700 | 1 | _aKivrak, Arif | |
| 700 | 1 | _aUlaş, Berdan | |
| 700 | 1 | _aKivrak, Hilal | |
| 856 | _uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703546/pdf/main.pdf | ||
| 942 | _cCV | ||
| 999 |
_c2667 _d2667 |
||